We are creating a paradigm shift in cancer immunotherapy by enhancing immune stemness, while neutralizing immunosuppressive mechanisms within the tumor microenvironment.
Current cancer immunotherapies—including immune checkpoint inhibitors, CAR-T cell therapies, T-cell engagers, cancer vaccines, and oncolytic viruses—can elicit strong initial antitumor responses. However, durable efficacy is often limited due to:
We designed a novel platform technology: HEXimunTM to:
HEXimun TM acts on downstream regulators of T-cell fate, influencing metabolic fitness to maintain TCF-1–dependent progenitor-like T cells during antigen stimulation. Unlike cytokine-based approaches (IL-7, IL-15 or IL-2) that primarily amplify proliferation or activation, HexImun is designed to influence & stabilize differentiation trajectories, without accelerating terminal exhaustion. Across multiple pre-clinical models, HexImun exhibited enrichment of stem-like T-cell phenotypic markers while maintaining regulated expression of activation-associated markers. Functional analyses demonstrated preserved proliferative capacity, robust recall responses, and maintained mitochondrial reserve. This mechanism supports multiple development contexts, including stand-alone cancer immunotherapeutics, combinations with immune checkpoint blockade or T-cell engagers, cancer vaccines, and CAR-T cell therapies.
Our team has prominent scientists, experts from the pharma industry, and entrepreneurs capable of providing specific domain expertise to accomplish various stages of development.
Magvitae Innovations welcomes discussions with strategic partners interested in co-developing next-generation, versatile immunotherapeutics. To explore collaboration opportunities, please contact info@magvitae.com.
Johns Hopkins Technology Ventures
1812 Ashland Avenue
Suite 110
Baltimore MD 21205
